SEARCH

SEARCH BY CITATION

References

  • 1
    Loftus JEV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population- based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 5160.
  • 2
    Mendeloff AICB. The epidemiology of idiopathic inflammatory bowel disease. In: KirsnerJBSR, ed. Inflammatory Bowel Disease. Philadelphia: Lea & Febiger, 1988: 334.
  • 3
    Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109(1): 12935.
  • 4
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340(18): 1398405.
  • 5
    Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. N Engl J Med 1997; 337(15): 102935.
  • 6
    Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137(2): 1926.
  • 7
    D'Haens G, Van Deventer SJH, Van Hogezand RA, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116(5): 102934.
  • 8
    Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95(12): 346977.
    Direct Link:
  • 9
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the Accent I randomised trial. Lancet 2002; 359: 15419.
  • 10
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117(4): 7619.
  • 11
    Lipsky PE, Van Der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343(22): 1594602.
  • 12
    Centocor. Remicade: Infliximab Full Product Labeling. Malvern: PA. Centocor, Inc., 9 November, 1999.
  • 13
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Hurd LB, Baldassano RN. Incidence of infusion reaction in patients receiving infliximab at a pediatric center. J Pediatr Gastroenterol Nutr 2001; 33(3): 3756.
  • 14
    Chehade MA, Pittman NS, Birnbaum AH, Benkov KJ. Clinical experience with infliximab therapy in pediatric patients with Crohn's disease. J Pediatr Gastroenterol Nutr 2001; 33(3): 375.
  • 15
    Kugathasan S, Vasilopoulos S, Emmons JE, et al. Allergic reactions to infliximab retreatment are decreased in pediatric Crohn's disease (CD) patients compared to adults. Gastroenterology 2001; 120(5 Suppl. 1): A69.
  • 16
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123(2): 13242.
  • 17
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302(18): 9817.
  • 18
    Menard S. Applied Logistic Regression Analysis. Thousand Oaks, CA: Sage Publications, 1995.
  • 19
    Hauck WW, Donner A. Wald's test as applied to hypotheses in logit analysis. J Am Statist Assoc 1977; 72: 8513.
  • 20
    Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13(4): 1622.
  • 21
    Han PD, Cohen RD, Motamedi F, Hanauer SB. Infliximab infusion reactions. The influence of sex and drugs. Gastroenterology 2002; 122(4[Suppl.]): A612.
  • 22
    Cannon JG, St. Pierre BA. Gender differences in host defense mechanisms. J Psychiat Res 1997; 31(1): 99113.
  • 23
    Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001; 1: 98393.